TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 سبتمبر 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 أغسطس 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 أغسطس 2022 04:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 أغسطس 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 أغسطس 2022 04:00:02 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 أغسطس 2022 13:05:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 يوليو 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 يوليو 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 يونيو 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

02 يونيو 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

17 مايو 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

16 مايو 2022 04:00:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 مايو 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2022 Financial Results

05 مايو 2022 13:01:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

03 مايو 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2022 Financial Results

28 أبريل 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

20 أبريل 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 أبريل 2022 14:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

06 أبريل 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

21 مارس 2022 04:00:01 بحسب Nasdaq GlobeNewswire